Abstract | BACKGROUND AND AIMS: SUBJECTS AND METHODS: Groups were designed as parallel and the study was designed as quasi-experimental and conducted at a semi-closed ICU between September 2008 and May 2010. Patients received 3.375 g ( piperacillin 3 g/ tazobactam 0.375 g) either through intermittent infusion every 6 h for 30 min [Intermittent Infusion (II) group; n = 30] or through continuous infusion every 8 h for 4 h [Continuous Infusion (CI) group; n = 31]. CPIS was used to assess the clinical diagnosis and outcome of VAP patients. RESULTS: Sex, age, Acute Physiology and Chronic Health Evaluation II II score on ICU admission, diagnosis and underlying disease of VAP patients were not significantly different in the CI (n = 31) and II ( n = 30) groups. Duration of mechanical ventilation, length of stay, total number of antibiotics used per patient and duration of piperacillin/tazobactam treatment were similar in both groups. Mortality rates of VAP patients were similar between both groups during hospitalization. CONCLUSION: There was no significant difference in clinical outcomes of patients receiving piperacillin-tazobactam via CI or II when measured by serial CPIS score.
|
Authors | Fanak Fahimi, Somayeh Ghafari, Hamidreza Jamaati, Shadi Baniasadi, Payam Tabarsi, Arvin Najafi, Arnavaz Akhzarmehr, Seyed Mohammad Reza Hashemian |
Journal | Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
(Indian J Crit Care Med)
Vol. 16
Issue 3
Pg. 141-7
(Jul 2012)
ISSN: 1998-359X [Electronic] India |
PMID | 23188954
(Publication Type: Journal Article)
|